Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DE:DYF1)
STUTTGART:DYF1
Dynavax (DYF1) Stock Price & Analysis
0 Followers
DYF1 Stock Chart & Stats
Day’s Range€10.42 - €10.43
52-Week Range― - ―
Previous Close€10.78
Volume0.00
Average Volume (3M)N/A
Market Cap
€1.43B
Enterprise Value€997.67M
Total Cash (Recent Filing)$720.42M
Total Debt (Recent Filing)$253.09M
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 08, 2024EPS Estimate
-€0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit2.17
Enterprise Value/Ebitda20.02
Forecast
1Y Price Target
€24.00Price Target Upside130.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Dynavax News
PremiumCompany Announcements
Dynavax Appoints Interim CFO During MacDonald’s Leave
PremiumCompany Announcements
Dynavax Secures New Sublease Agreement Amidst Zymergen’s Bankruptcy
Bulls Say, Bears Say
Bulls Say
Financial OutlookDynavax expects a robust financial outlook as it projects to be cash-flow positive, thanks to its impressive cash position and strategic plans to diversify its product pipeline.
Market GrowthDynavax forecasts the Hepatitis B vaccine market will see substantial growth annually, driven by updated guidelines, which suggests a promising expanding market for Heplisav-B.
Product PerformanceHeplisav-B sales rose significantly, with market share and gross margin continuing to grow, underlining the vaccine's strong performance and increasing acceptance.
Bears Say
Health Epidemics ImpactRSV/flu/COVID-19 hit 4Q HEPLISAV-B and linger into 1Q24, negatively impacting HEPLISAV-B uptake.
Sales ImpactQ4 sales were impacted by seasonality and heightened competition from the launch of 2 RSV vaccines, along with COVID re-vaccinations and flu immunizations.
Stock PerformanceLimited potential upside for DVAX shares from current levels given the mostly early stage pipeline and scarcity of near-term catalysts.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
5.22% Other Institutional Investors
94.78% Public Companies and
Individual Investors
DYF1 FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Currently, no data Available
What is Dynavax Technologies Corp.’s market cap?
Currently, no data Available
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is May 08, 2024 which is in 11 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Feb 22, 2024. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.01 by €0.01.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is -€0.02.
How many shares outstanding does Dynavax Technologies Corp. have?
Currently, no data Available
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of €0 in its last earnings report, beating expectations of -€0.01. Following the earnings report the stock price went up 0.742%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Among the largest hedge funds holding Dynavax Technologies Corp.’s share is Driehaus Capital Management LLC. It holds Dynavax Technologies Corp.’s shares valued at 22M.
---
Dynavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€24.00 (130.26% Upside)
€24.00 (130.26% Upside)
Blogger Sentiment
Bullish
DE:DYF1 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.10%
12-Months-Change
Fundamentals
Return on Equity
-1.06%
Trailing 12-Months
Asset Growth
1.14%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DYF1 Company Deck
---
DYF1 Earnings Call
Q4 2024
0:00 / 0:00
---
DYF1 Stock 12 Months Forecast
Average Price Target
€24.00
▲(130.26% Upside)
Technical Analysis
Best Analysts Covering DYF1
1 Year
1 Year Success Rate
11/25 ratings generated profit
1 Year Average Return
+1.36%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 44.00% of your transactions generating a profit, with an average return of +1.36% per trade.
---